OBJECTIVES: Upon completion of this activity, the participant should be able to:

Objective 1)  Recognize limitations in the evaluation of kidney function with creatinine-based estimates of GFR among patients with cirrhosis

Objective 2)  Review alternative biomarkers with the potential to more accurately evaluate kidney function in patients with decompensated cirrhosis

Objective 3)  Discuss cystatin C as a viable means to estimate GFR in patients with cirrhosis who are disadvantaged by creatine-based estimates of GFR and risk stratification including the MELD score

FACULTY DISCLOSURE:

Stevan A. Gonzalez, MD, MS

Mallinckrodt Pharmaceuticals - Consulting, Advisory Board

Salix Pharmaceuticals - Consulting, Speaker

Intercept Pharmaceuticals - Consulting (Relationship has ended)

AbbVie Pharmaceuticals - Speaker (Relationship has ended)

PLANNER DISCLOSURE:  Dr. Michael Mack, Jennifer Thomas, BS, MS;  Alaina Tellson PhD, RN, NPD-BC, NE-BC; have no relevant financial relationship(s) to disclose with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships have been mitigated.

ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES: Baylor Scott & White Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.